NVCR
NovoCure Limited·Healthcare
16.99
6.955%(−1.27)
Close PriceLast Updated: — ET
52W L: $9.8252W H: $20.06
NVCR NEWS
fool.com
May 5
3 Overlooked Stocks Set to Soar in 2026
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.
zacks.com
May 4
International Markets and NovoCure (NVCR): A Deep Dive for Investors
Review NovoCure's (NVCR) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
seekingalpha.com
May 1
NovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer Yet
NovoCure Limited has resolved its CMS billing issue, with no material impact on operations or financials. Q1 2026 revenues grew 12% year-over-year to $174.1M; gross margins improved to 78%, and full-year guidance was raised to $690–710M. Optune Pax launch shows promising demand, but sustainability remains uncertain; Optune Lua for lung cancer has disappointed.
seekingalpha.com
Apr 30
NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript
NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript
zacks.com
Apr 30
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
NovoCure (NVCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.31 per share a year ago.
businesswire.com
Apr 30
Novocure Reports First Quarter 2026 Financial Results
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “This was a very strong start to the year for Novocure and we are pleased with the progress made across our commercial and clinical programs,” said Frank.
